Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Giresun Training and Research Hospital | UNKNOWN |
| St. Mary's University, Twickenham | OTHER |
| Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale | NETWORK |
Not provided
Not provided
Not provided
Not provided
The aim of this study is to evaluate the Turkish validity and reliability of the Patient Reported Outcomes for Fighting Financial Toxicity of Cancer (PROFFIT) developed in Italy.
The scale validity of the study will be evaluated through language and content validity, construct validity, criterion validity, and known-group validity methods; while the scale reliability will be assessed by calculating the Cronbach's alpha and McDonald's omega reliability coefficients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Validity Assessment-Language and Content Validity | Language and Content Validity: To assess the relevance and appropriateness of the translated items, a panel of at least six experts in oncology, psychology, and instrument development will evaluate each item. | Through study completion, an average of 12 months |
| Validity Assessment-Content Validity Index (CVI) | Content Validity Index (CVI) will be calculated based on expert ratings to determine the proportion of items deemed relevant. | Through study completion, an average of 12 months |
| Validity Assessment-Content Validity Ratio (CVR) | Content Validity Ratio (CVR) will be used to assess whether each item is essential for measuring the construct. | Through study completion, an average of 12 months |
| Validity Assessment-Construct Validity | Confirmatory Factor Analysis (CFA) will be performed to verify whether the factor structure of the Turkish version aligns with that of the original instrument. Model fit indices such as χ²/df, RMSEA, CFI, TLI, and SRMR will be used to evaluate the adequacy of the factor structure. | Through study completion, an average of 12 months |
| Validity Assessment- Criterion Validity | The Turkish PROFFIT scores will be correlated with other established patient-reported outcome measures, specifically the COST (v2) and EORTC QLQ-C30 instruments, to assess convergent validity. Pearson or Spearman correlation coefficients will be used to determine the strength of associations between PROFFIT and these validated measures. | Through study completion, an average of 12 months |
| Validity Assessment- Known-Group Validity |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Turkish-speaking and literate volunteers over the age of 18 diagnosed with solid cancer or hematologic malignancy who have received cancer treatment (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, radiotherapy, or a combination of these treatments) within the last three months.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Zeynep Karakuş, PhD | Contact | +902423102965 | zeynepkarakus@akdeniz.edu.tr | |
| Zeynep Özer, PhD | Contact |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess whether the instrument can differentiate between groups with known differences in financial toxicity, mean scores of the total and subscales will be compared across predefined demographic and clinical groups. Independent samples t-tests and ANOVA will be performed to compare group differences. |
| Through study completion, an average of 12 months |
| Reliability Assessment | Internal Consistency: The reliability of the Turkish PROFFIT instrument will be evaluated using: Cronbach's alpha (α) to assess the overall internal consistency of the scale. McDonald's omega (ω) as an alternative measure that provides a more robust estimation of reliability in multidimensional scales. | Through study completion, an average of 12 months |